Asimov’s LV Edge Packaging cell line routinely achieves high titers for therapeutic transgenes and is now available at AGC Biologics’ Cell and Gene Center of Excellence Asimov, the synthetic biology ...

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces ...

Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...

Technologies used for cell and gene therapy development have come a long way but there are still important challenges associated with lentivirus manufacture. GMP plasmids account for a substantial ...

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the expansion of its LV Edge System with the launch of a fully stable cell line development ...

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, and AGC Biologics, your friendly CDMO expert, have signed a licensing agreement for Asimov’s off-the-shelf ...